Nonsteroidal anti-inflammatory drugs (NSAIDs) like coxibs (celecoxib, rofecoxib, valdecoxib) 88, etodolac 89, and NS-398 88, are notable cancer prevention agents that inhibit COX-2 by elevating ROS concentrations, thereby reducing cancer recurrence. This evidence concerns the gene PTGS2 and cancer.